ECMO bleeding mystery: new study probes hidden clotting defects

NCT ID NCT03070912

Completed Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 257 emergency patients on ECMO (a heart-lung machine) to understand why many experience serious bleeding. Researchers measured how often bleeding occurred and checked for defects in von Willebrand factor, a key clotting protein. The goal is to find links between ECMO type and bleeding risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better predict and manage bleeding in patients on ECMO support.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to direct changes in care, and results may not apply to all ECMO patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemorrhage hereditary von Willebrand disease von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VON WILLEBRAND DISEASES

Contacts and locations

Locations

CH ARRAS

Arras, France
CH Boulogne

Boulogne-sur-Mer, France
CH DOUAI

Douai, France
CH Dunkerque

Dunkirk, 59385, France
Ch Tourcoing

Tourcoing, France
Ch Valenciennes

Valenciennes, France
Hôpital Cardiologie, CHU

Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.